Vaxcyte (PCVX) Valuation Check As VAX-31 Phase 3 OPUS Trials Reach Full Enrollment

Simply Wall St.04-05

Vaxcyte (PCVX) recently reported full enrollment in its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, a key step toward a potential Biologics License Application that investors often monitor closely. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625611939?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-05 02:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625611939","market":"nz","top_or_hot":-1,"title":"Vaxcyte (PCVX) Valuation Check As VAX-31 Phase 3 OPUS Trials Reach Full Enrollment","media":"Simply Wall St.","content":"<div>\n<p>Vaxcyte (PCVX) recently reported full enrollment in its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, a key step toward a potential Biologics License Application that investors often monitor closely. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-valuation-check-as-vax-31-phase-3-opus-trials-r\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxcyte (PCVX) Valuation Check As VAX-31 Phase 3 OPUS Trials Reach Full Enrollment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxcyte (PCVX) Valuation Check As VAX-31 Phase 3 OPUS Trials Reach Full Enrollment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-05 02:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-valuation-check-as-vax-31-phase-3-opus-trials-r><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaxcyte (PCVX) recently reported full enrollment in its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, a key step toward a potential Biologics License Application that investors often monitor closely. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-valuation-check-as-vax-31-phase-3-opus-trials-r\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009354923.USD","symbol_name":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-valuation-check-as-vax-31-phase-3-opus-trials-r","article_id":"2625611939","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-valuation-check-as-vax-31-phase-3-opus-trials-r","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625611939","pubTimestamp":1775326450,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Vaxcyte (PCVX) recently reported full enrollment in its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, a key step toward a potential Biologics License Application that investors often monitor closely.\nSee our latest analysis for Vaxcyte.\nThe recent completion of enrollment in the OPUS-1 and OPUS-2 trials comes alongside strong momentum, with a 90 day share price return of 25.66% and a 1 year total shareholder return of 84.75%, while the latest share price stands at US$58.38.\nIf this kind of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","OPUS":"OPUS MAGNUM AMERIS, INC.","PCVX":"Vaxcyte, Inc.","BK4139":"生物科技","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"随着VAX-31 3期OPUS试验全面入组，Vaxcyte(PCVX)进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPUS":1.5,"PCVX":1.5},"content_text":"Vaxcyte (PCVX) recently reported full enrollment in its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, a key step toward a potential Biologics License Application that investors often monitor closely. See our latest analysis for Vaxcyte. The recent completion of enrollment in the OPUS-1 and OPUS-2 trials comes alongside strong momentum, with a 90 day share price return of 25.66% and a 1 year total shareholder return of 84.75%, while the latest share price stands at US$58.38. If this kind of clinical progress has your attention, it can be useful to see what else is moving in related areas by scanning 36 healthcare AI stocks. With shares up 25.66% over 90 days and trading at US$58.38 against an implied intrinsic discount of roughly 36%, the key question now is simple: is Vaxcyte still mispriced or has the market already priced in future growth? AdvertisementMost Popular Narrative: 46.4% Undervalued With Vaxcyte last closing at $58.38 against a narrative fair value of $109.00, the valuation gap hinges heavily on what happens with VAX-31 and broader vaccine demand.  Expanded adult pneumococcal vaccination recommendations in the US and increasing adoption of adult PCV programs internationally are enlarging the addressable market for higher valency vaccines such as VAX-31. This directly relates to potential future revenue scale.  Read the complete narrative. Want to understand why this pre revenue company still screens as deeply undervalued? The core narrative leans on aggressive revenue ramp assumptions, margin uplift from maturing biotech peers, and a premium future earnings multiple rarely seen outside high growth sectors. Result: Fair Value of $109 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on OPUS and infant VAX-31 data meeting expectations and on Vaxcyte managing rising R&D and manufacturing costs without eroding its cash runway. Find out about the key risks to this Vaxcyte narrative. Next Steps Think this story sounds either too optimistic or too cautious? Take a closer look at the full picture for yourself, including the 1 key reward and 2 important warning signs Ready for more investment ideas? If Vaxcyte has sharpened your focus, do not stop here. Broaden your watchlist with targeted ideas that could fit different goals and risk levels.  Spot potential turnaround stories early by scanning 33 elite penny stocks with strong financials that meet clear financial quality filters instead of guessing on the riskiest names. Zero in on quality at a discount by reviewing the 59 high quality undervalued stocks that combine strong fundamentals with attractive pricing signals. Build a steadier income focused watchlist by checking out the 13 dividend fortresses that pair higher yields with a focus on resilience.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625611939","isCrawlerRequest":true}